TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 28296349

Group type: EXPERIMENTAL
Intervention: DPP-4 inhibitors
Number of subjects: 0

Group type: COMPARATOR
Intervention: Biguanides (BG)
Number of subjects: 0

Group type: COMPARATOR
Intervention: α-glucosidase inhibitors (αGI)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sulfonylureas (SU)
Number of subjects: 0
Study: 27385157

Group type: EXPERIMENTAL
Intervention: Lorcaserin
Number of subjects: 48

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study: 24164420

Group type: EXPERIMENTAL
Intervention: Letermovir 40 mg twice a day
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Letermovir 80 mg once a day
Number of subjects: 27

Group type: COMPARATOR
Intervention: Standard of Care (SOC)
Number of subjects: 27
Study: 22741260

Group type: EXPERIMENTAL
Intervention: Electroacupuncture at 2 Hz (Group II)
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Electroacupuncture at 2 Hz/100 Hz (Group III)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Control group (Group I)
Number of subjects: 56
Study: 20522788

Group type: EXPERIMENTAL
Intervention: Enteral probiotics (Lactobacillus rhamnosus GG)
Number of subjects: 146

Group type: COMPARATOR
Intervention: Placebo (inert inulin-based)
Number of subjects: 146
Study: 18458306

Group type: EXPERIMENTAL
Intervention: Primaquine, 30 mg a day for 5 days
Number of subjects: 399

Group type: EXPERIMENTAL
Intervention: Primaquine, 30 mg a day for 7 days
Number of subjects: 399

Group type: EXPERIMENTAL
Intervention: Primaquine, 30 mg a day for 9 days
Number of subjects: 399

Group type: EXPERIMENTAL
Intervention: Primaquine, 30 mg a day for 11 days
Number of subjects: 399

Group type: EXPERIMENTAL
Intervention: Primaquine, 30 mg a day for 14 days
Number of subjects: 399

Group type: EXPERIMENTAL
Intervention: Primaquine, 30 mg twice a day for 7 days
Number of subjects: 399
Study: 15670541

Group type: EXPERIMENTAL
Intervention: Culprit lesion calcium (CLC)
Number of subjects: 3292
Study: 12603644

Group type: EXPERIMENTAL
Intervention: Schultz-type autogenic training
Number of subjects: 25
Study: 11253883

Group type: EXPERIMENTAL
Intervention: Intracameral pilocarpine (0.13 mg/ml in BSS)
Number of subjects: 30

Group type: COMPARATOR
Intervention: BSS (control group)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Intracameral pilocarpine
Number of subjects: 30
Study: 9456075

Group type: EXPERIMENTAL
Intervention: Controlled intervention programs aimed at enhancing organizational structures and individual coping strategies
Number of subjects: 0

Group type: COMPARATOR
Intervention: Regular video display technology
Number of subjects: 0
Study: 1544615

Group type: EXPERIMENTAL
Intervention: Ginkgo biloba extract EGb 761
Number of subjects: 72

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 72
Study: 3885685

Group type: EXPERIMENTAL
Intervention: Internal neurolysis
Number of subjects: 0

Group type: COMPARATOR
Intervention: Cutting of the carpal ligament (flexor retinaculum) alone
Number of subjects: 0
Study: 31168046

Group type: EXPERIMENTAL
Intervention: Percutaneous coronary intervention (PCI) for STEMI
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Fractional flow reserve (FFR)-guided PCI for AP
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: FFR-guided PCI for asymptomatic patients
Number of subjects: 2

Group type: COMPARATOR
Intervention: Medical therapy for STEMI
Number of subjects: 2

Group type: COMPARATOR
Intervention: Medical therapy for AP
Number of subjects: 2
Study: 29338727

Group type: EXPERIMENTAL
Intervention: Common Hp genotypes
Number of subjects: 5687

Group type: EXPERIMENTAL
Intervention: Serum Hp levels
Number of subjects: 5687

Group type: EXPERIMENTAL
Intervention: Common Hp genotypes and Hp levels
Number of subjects: 5687
Study: 26786091

Group type: EXPERIMENTAL
Intervention: Pasireotide
Number of subjects: 300

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 300
Study: 24714360

Group type: EXPERIMENTAL
Intervention: Bacille Calmette-Guérin (BCG) vaccination at birth
Number of subjects: 390

Group type: COMPARATOR
Intervention: Low cytokine responses to LPS and PHA
Number of subjects: 390

Group type: COMPARATOR
Intervention: High cytokine responses to LPS and PHA
Number of subjects: 390
Study: 22669229

Group type: EXPERIMENTAL
Intervention: Multimodal hand hygiene improvement strategy (training sessions, hydroalcoholic solutions, reminder posters)
Number of subjects: 198

Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 198
Study: 21290360

Group type: EXPERIMENTAL
Intervention: Simulation session (n=26), 30-minute hands-on session
Number of subjects: 50

Group type: COMPARATOR
Intervention: Image-based interactive lecture (n=24), 30-minute session
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Simulation session (n=26)
Number of subjects: 50
Study: 18044562

Group type: EXPERIMENTAL
Intervention: Discriminative model based on fMRI and anatomical template
Number of subjects: 83

Group type: COMPARATOR
Intervention: Anatomical parcellation process
Number of subjects: 83
Study: 15954910

Group type: EXPERIMENTAL
Intervention: Long-acting somatostatin (octreotide-LAR, 40 mg intramuscularly every 28 days)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 12410487

Group type: EXPERIMENTAL
Intervention: Recombinant human growth hormone (GH) at a dose of 0.1 mg/kg/day
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 11030804

Group type: EXPERIMENTAL
Intervention: Vitamin E supplementation (50 mg)
Number of subjects: 28519

Group type: EXPERIMENTAL
Intervention: Beta carotene supplementation (20 mg)
Number of subjects: 28519

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28519
Study: 8835043

Group type: EXPERIMENTAL
Intervention: Amoxicillin (Trimox)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Amoxicillin (Amoxil)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Penicillin VK (V-Cillin-K)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Penicillin VK (PenVee K)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Penicillin VK (VeeTids)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Penicillin VK (overall)
Number of subjects: 30
Study: 1568570

Group type: COMPARATOR
Intervention: NSAID + placebo
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: NSAID + misoprostol
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Misoprostol alone
Number of subjects: 20
Study: 3858912

Group type: EXPERIMENTAL
Intervention: 1 mug PGEsub 1‐carbinol
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: 10 mug PGEsub 1‐carbinol
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: 30 mug PGEsub 1‐carbinol
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: 55 mug PGEsub 2
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo (10% ethanol in normal saline)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: 400 mug fenoterol
Number of subjects: 15
Study: 31953303

Group type: EXPERIMENTAL
Intervention: Tacrolimus (0.05 mg/kg twice daily)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Prednisolone (1 mg/kg daily up to 60 mg daily)
Number of subjects: 50
Study: 31640110

Group type: EXPERIMENTAL
Intervention: Active Play!
Number of subjects: 97

Group type: EXPERIMENTAL
Intervention: Outdoor Play!
Number of subjects: 97
Study: 28931411

Group type: EXPERIMENTAL
Intervention: Topiramate (100 mg per day as add-on therapy to antipsychotics)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Placebo (treatment as usual with antipsychotics)
Number of subjects: 90
Study: 26167680

Group type: EXPERIMENTAL
Intervention: Individualized-protocol with adjusted injection rate based on patient weight and contrast medium concentration (280 mgI/kg)
Number of subjects: 160

Group type: COMPARATOR
Intervention: Conventional contrast injection protocol with total injection volume of 80ml and constant injection rate of 5.5ml/s
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Individualized-protocol
Number of subjects: 160
Study: 23978513

Group type: EXPERIMENTAL
Intervention: Inhibitory TBS
Number of subjects: 12

Group type: COMPARATOR
Intervention: Sham TBS
Number of subjects: 12
Study: 21519151

Group type: EXPERIMENTAL
Intervention: β-blockade with metoprolol (up to 50mg b.i.d.) or carvedilol (up to 25mg b.i.d.)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Control (ACE inhibitor treatment without β-blockade)
Number of subjects: 21
Study: 18482349

Group type: EXPERIMENTAL
Intervention: Polymer crowns with a glass-fibre framework (group 1)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Polymer crowns without framework stabilization (group 2)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Metal-ceramic crowns (control group)
Number of subjects: 120
Study: 16413644

Group type: EXPERIMENTAL
Intervention: Meaning-making intervention (up to four sessions exploring emotional responses and cognitive appraisals)
Number of subjects: 82

Group type: COMPARATOR
Intervention: Routine care (control group)
Number of subjects: 82
Study: 12616233

Group type: EXPERIMENTAL
Intervention: Double-arch impression technique
Number of subjects: 50

Group type: COMPARATOR
Intervention: Complete-arch impression technique
Number of subjects: 50
Study: 10714475

Group type: EXPERIMENTAL
Intervention: 5-day moxifloxacin 400 mg once daily
Number of subjects: 936

Group type: EXPERIMENTAL
Intervention: 10-day moxifloxacin 400 mg once daily
Number of subjects: 936

Group type: COMPARATOR
Intervention: 10-day clarithromycin 500 mg bid
Number of subjects: 936
Study: 9257090

Group type: EXPERIMENTAL
Intervention: Oligoantigenic diet
Number of subjects: 49

Group type: COMPARATOR
Intervention: Methylphenidate
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Both treatments (Oligoantigenic diet and Methylphenidate)
Number of subjects: 49
Study: 8299614

Group type: EXPERIMENTAL
Intervention: Vitamin C (400 mg)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Vitamin E (400 mg)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo (400 mg)
Number of subjects: 24
Study: 3829298

Group type: EXPERIMENTAL
Intervention: Isoflurane (ISO)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Sodium nitroprusside (SNP)
Number of subjects: 16
Study: 31741148

Group type: EXPERIMENTAL
Intervention: Navilas laser
Number of subjects: 70

Group type: COMPARATOR
Intervention: Conventional single-spot laser
Number of subjects: 70
Study: 29461660

Group type: EXPERIMENTAL
Intervention: Belatacept (more intense-based)
Number of subjects: 1209

Group type: EXPERIMENTAL
Intervention: Belatacept (less intense-based)
Number of subjects: 1209

Group type: EXPERIMENTAL
Intervention: Belatacept
Number of subjects: 1209

Group type: COMPARATOR
Intervention: Cyclosporine
Number of subjects: 1209

Group type: EXPERIMENTAL
Intervention: Belatacept (black patients)
Number of subjects: 1209

Group type: COMPARATOR
Intervention: Cyclosporine (black patients)
Number of subjects: 1209

Group type: EXPERIMENTAL
Intervention: Belatacept and Cyclosporine
Number of subjects: 1209
Study: 29178932

Group type: EXPERIMENTAL
Intervention: Herbst appliance with dental anchorage
Number of subjects: 0

Group type: COMPARATOR
Intervention: Herbst appliance with skeletal anchorage
Number of subjects: 0
Study: 25637849

Group type: EXPERIMENTAL
Intervention: MiniArc
Number of subjects: 225

Group type: COMPARATOR
Intervention: Monarc
Number of subjects: 225
Study: 21652093

Group type: EXPERIMENTAL
Intervention: Bisoprolol
Number of subjects: 883

Group type: COMPARATOR
Intervention: Carvedilol
Number of subjects: 883

Group type: EXPERIMENTAL
Intervention: Self-rated health (SRH) assessment
Number of subjects: 883
Study: 20861065

Group type: EXPERIMENTAL
Intervention: Mirror condition (observing mirror reflection of the unaffected hand)
Number of subjects: 22

Group type: COMPARATOR
Intervention: No-mirror condition (observing affected hand directly)
Number of subjects: 22
Study: 18801303

Group type: EXPERIMENTAL
Intervention: Rocuronium 0.6 mg/kg initial dose followed by 0.15 mg/kg repeated doses
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Rocuronium 0.15 mg/kg repeated doses
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Rocuronium
Number of subjects: 60
Study: 17201213

Group type: EXPERIMENTAL
Intervention: Electroimpulse therapy
Number of subjects: 0
Study: 14733347

Group type: EXPERIMENTAL
Intervention: Orthotripsy (extracorporeal shock waves)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Orthotripsy (after crossover from placebo)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Orthotripsy (for patients with longest symptom duration)
Number of subjects: 0
Study: 10878703

Group type: EXPERIMENTAL
Intervention: Complete androgen deprivation
Number of subjects: 24

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 24
Study: 9366716

Group type: EXPERIMENTAL
Intervention: Immunonutrition group (n = 87)
Number of subjects: 260

Group type: COMPARATOR
Intervention: Standard group (n = 87)
Number of subjects: 260

Group type: COMPARATOR
Intervention: Parenteral group (n = 86)
Number of subjects: 260
Study: 8040780

Group type: EXPERIMENTAL
Intervention: Formula A (3.0 gm/100 kcal)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Formula B (2.7 gm/100 kcal)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Formula C (2.2 gm/100 kcal)
Number of subjects: 27
Study: 2737225

Group type: EXPERIMENTAL
Intervention: Alifedrine 40 mg
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Alifedrine 50 mg
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Alifedrine 60 mg
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 31139998

Group type: EXPERIMENTAL
Intervention: First-person perspective e-learning videos
Number of subjects: 91

Group type: COMPARATOR
Intervention: Endoscopic view only e-learning videos
Number of subjects: 91
Study: 30958065

Group type: EXPERIMENTAL
Intervention: Pulse Oximetry (PO)
Number of subjects: 94

Group type: COMPARATOR
Intervention: Doppler Ultrasound (DU)
Number of subjects: 94
Study: 28151719

Group type: EXPERIMENTAL
Intervention: Enzalutamide (enza)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Enzalutamide + Dutasteride + LHRHa (enza/dut/LHRHa)
Number of subjects: 48
Study: 27132448

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Number of subjects: 90

Group type: COMPARATOR
Intervention: Midazolam
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Both drugs
Number of subjects: 90
Study: 22903362

Group type: EXPERIMENTAL
Intervention: Moderate gymnastics training programme
Number of subjects: 53

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 53
Study: 21063431

Group type: EXPERIMENTAL
Intervention: Fish oil concentrate with EPA+DHA (1.01g+0.67g) as reesterified triacylglycerides (rTAG group)
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Fish oil concentrate with EPA+DHA (1.01g+0.67g) as ethyl ester (EE group)
Number of subjects: 150

Group type: COMPARATOR
Intervention: Corn oil (placebo group)
Number of subjects: 150
Study: 19305319

Group type: EXPERIMENTAL
Intervention: Transvaginal ultrasonography and CA 125 screening
Number of subjects: 34261

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 34261
Study: 17445351

Group type: EXPERIMENTAL
Intervention: Daily consumption of 1440 kJ serving of almonds for 10 weeks
Number of subjects: 20

Group type: COMPARATOR
Intervention: Customary diet for 10 weeks (control)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Daily consumption of almonds
Number of subjects: 20
Study: 15239282

Group type: EXPERIMENTAL
Intervention: Roux‐Y (n=18)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Billroth I (n=25)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Billroth II (n=17)
Number of subjects: 60
Study: 11590218

Group type: EXPERIMENTAL
Intervention: Palm oil
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Transesterified palm oil
Number of subjects: 10
Study: 9671372

Group type: EXPERIMENTAL
Intervention: Conditioned media from isolated human mononuclear cells
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control media
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Dimethylphenylpiperazinium (10 microM)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Conditioned media from mixed leukocyte reaction
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Dexamethasone pretreatment
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cytokines IL-1 and IL-2 (50 and 500 units/well)
Number of subjects: 0
Study: 7672677

Group type: EXPERIMENTAL
Intervention: Omeprazole 20 mg twice daily plus amoxicillin 1 g twice daily
Number of subjects: 50

Group type: COMPARATOR
Intervention: Omeprazole 40 mg twice daily plus amoxicillin 1 g twice daily
Number of subjects: 50
Study: 2376846

Group type: EXPERIMENTAL
Intervention: Repressive coping style
Number of subjects: 120
Study: 7211811

Group type: EXPERIMENTAL
Intervention: Gentamicin
Number of subjects: 61

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 61
Study: 31387417

Group type: EXPERIMENTAL
Intervention: BI 695501 (Group A)
Number of subjects: 430

Group type: EXPERIMENTAL
Intervention: BI 695501 (Group B)
Number of subjects: 430

Group type: COMPARATOR
Intervention: Adalimumab RP (Group C)
Number of subjects: 430
Study: 28506150

Group type: EXPERIMENTAL
Intervention: Fast movement training (420 repetitions/day)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Slow movement training (420 repetitions/day)
Number of subjects: 36
Study: 25752740

Group type: EXPERIMENTAL
Intervention: Lapatinib
Number of subjects: 3074

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3074
Study: 23636199

Group type: EXPERIMENTAL
Intervention: Virtual simulator
Number of subjects: 22

Group type: COMPARATOR
Intervention: Sawbones simulator
Number of subjects: 22
Study: 22194814

Group type: EXPERIMENTAL
Intervention: Graded calf compression stockings
Number of subjects: 15

Group type: COMPARATOR
Intervention: Calf placebo stockings
Number of subjects: 15

Group type: COMPARATOR
Intervention: Ankle placebo stockings
Number of subjects: 15
Study: 19482879

Group type: EXPERIMENTAL
Intervention: Evening SMS intervention
Number of subjects: 70

Group type: COMPARATOR
Intervention: No evening SMS intervention (Control)
Number of subjects: 70
Study: 17037995

Group type: EXPERIMENTAL
Intervention: Proton pump inhibitors (PPIs); duration 8-16 weeks.
Number of subjects: 344

Group type: COMPARATOR
Intervention: Placebo; duration 8-16 weeks.
Number of subjects: 344
Study: 12632615

Group type: EXPERIMENTAL
Intervention: Colloid preloading (6% hydroxyethyl starch; HES) at 8 ml.kg‐1 before spinal anesthesia
Number of subjects: 20

Group type: COMPARATOR
Intervention: No prehydration (Control group)
Number of subjects: 20
Study: 11013810

Group type: EXPERIMENTAL
Intervention: Perioperative antibiotic prophylaxis (PAP) as per the quality standard developed in 1994.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: New randomized controlled studies on PAP.
Number of subjects: 0
Study: 1678643

Group type: EXPERIMENTAL
Intervention: 3 g of oral calcium supplementation/day for three months postoperatively
Number of subjects: 16

Group type: COMPARATOR
Intervention: Control (no calcium supplementation)
Number of subjects: 16
Study: 6605501

Group type: EXPERIMENTAL
Intervention: Augmentin
Number of subjects: 52

Group type: COMPARATOR
Intervention: Co-trimoxazole
Number of subjects: 52
Study: 30795773

Group type: EXPERIMENTAL
Intervention: Letrozole monotherapy
Number of subjects: 3021

Group type: EXPERIMENTAL
Intervention: Tamoxifen monotherapy
Number of subjects: 3021

Group type: EXPERIMENTAL
Intervention: AR expression
Number of subjects: 3021
Study: 29458517

Group type: EXPERIMENTAL
Intervention: Text warning labels
Number of subjects: 1200

Group type: EXPERIMENTAL
Intervention: Pictorial warning labels
Number of subjects: 1200

Group type: COMPARATOR
Intervention: Control group (water bottle labels)
Number of subjects: 1200
Study: 26376936

Group type: EXPERIMENTAL
Intervention: Spiritual history taking based on the ars moriendi model
Number of subjects: 49

Group type: COMPARATOR
Intervention: Care as usual (Control)
Number of subjects: 49
Study: 25294589

Group type: EXPERIMENTAL
Intervention: Edoxaban 30 mg once daily
Number of subjects: 716

Group type: COMPARATOR
Intervention: Enoxaparin 2000 IU subcutaneously twice daily
Number of subjects: 716

Group type: EXPERIMENTAL
Intervention: Edoxaban
Number of subjects: 716

Group type: COMPARATOR
Intervention: Enoxaparin
Number of subjects: 716
Study: 22516508

Group type: EXPERIMENTAL
Intervention: LEV XR 2000 mg/day
Number of subjects: 228

Group type: EXPERIMENTAL
Intervention: LEV XR 1000 mg/day
Number of subjects: 228

Group type: COMPARATOR
Intervention: Historical control
Number of subjects: 228
Study: 20353031

Group type: EXPERIMENTAL
Intervention: Zishen Shengxue Recipe (ZSR) combined with subcutaneous injection of erythropoiesis stimulating factor (rHuEpo)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group treated with rHuEpo alone
Number of subjects: 60
Study: 17569144

Group type: EXPERIMENTAL
Intervention: Nasojejunal enteral nutrition with prebiotic fiber supplementation
Number of subjects: 30

Group type: COMPARATOR
Intervention: Standard enteral nutrition
Number of subjects: 30
Study: 16144070

Group type: EXPERIMENTAL
Intervention: Pressure-reducing visco-elastic foam mattress (Pressurease)
Number of subjects: 21
Study: 12153828

Group type: EXPERIMENTAL
Intervention: Antidepressant medication (tricyclic antidepressants and phenelzine)
Number of subjects: 883

Group type: EXPERIMENTAL
Intervention: Psychotherapy (primarily cognitive behavior and interpersonal therapies)
Number of subjects: 883

Group type: COMPARATOR
Intervention: Control conditions
Number of subjects: 883

Group type: EXPERIMENTAL
Intervention: Antidepressant medication
Number of subjects: 883

Group type: EXPERIMENTAL
Intervention: Psychotherapy
Number of subjects: 883